Other Events ·
MoonLake Immunotherapeutics announced positive topline Week 16 results from its Phase 3 IZAR-1 trial of sonelokimab in…
MLTXMoonLake Immunotherapeutics
MoonLake Immunotherapeutics announced positive topline Week 16 results from its Phase 3 IZAR-1 trial of sonelokimab in biologic-naïve patients with psoriatic arthritis, meeting all clinical endpoints. The primary endpoint of ACR50 response was achieved by 42.1% of patients treated with the 60 mg dose, while secondary endpoints showed 66.5% achieving ACR20, 41.2% Minimal Disease Activity, and 61% PASI90. The company reported second quarter 2026 financial results, ending with $537.0 million in cash and equivalents, sufficient to fund operations through mid-2028. MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company developing sonelokimab for inflammatory diseases.